IPN10200

Phase 2Biologic

Ipsen

IPN10200 is one of 72 biologic programs targeting Cervical Dystonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

SpasticityActive, not recruiting

MigraineActive, not recruiting

Episodic MigraineRecruiting

Cervical DystoniaPhase 2

Active, not recruiting

SpasticityPhase 1/Phase 2

Active, not recruiting

MigrainePhase 2

Active, not recruiting

Episodic MigrainePhase 2

Recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Aimovig

Amgen

Preclinical

33 2

Emgality

Eli Lilly

Preclinical

19 3

IPN10200

Ipsen

Phase 2

6 4

Vyepti

Lundbeck

Preclinical

12 5

Bayer Aspirin

Bayer

Preclinical

2 6

Savella

AbbVie

Preclinical

2 7

Cymbalta

Alnylam Pharmaceuticals

Preclinical

1 8

Botox

RRevance Therapeutics, Inc.

Preclinical

9 9

Adempas

Bayer

Preclinical

1 10

Viagra

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Safety and Efficacy

NCT04821089

Q3 2027

Phase 3Recruiting

Effectiveness

NCT07427797

Q4 2027

Phase 1/2Recruiting

Spasticity

NCT04752774

Phase 2Recruiting

Episodic Migraine

NCT06625060

Phase 2Recruiting

Cervical Dystonia

NCT06937931

Q4 2028

Phase 3Recruiting

Effectiveness

NCT07435428

Clinical

Trials by Indication[1]

Effectiveness2 trials

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Recruiting· Ipsen logo

Ipsen·Phase 3·NCT07435428·1,300 enrolled

A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows

Recruiting· Ipsen logo

Ipsen·Phase 3·NCT07427797·300 enrolled

Safety and Efficacy1 trial

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

Recruiting· Ipsen logo

Ipsen·Phase 1/2·NCT04821089·727 enrolled

Spasticity1 trial

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

Recruiting· Ipsen logo

Ipsen·Phase 1/2·NCT04752774·240 enrolled

Episodic Migraine1 trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults

Recruiting· Ipsen logo

Ipsen·Phase 2·NCT06625060·641 enrolled

Cervical Dystonia1 trial

A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

Recruiting· Ipsen logo

Ipsen·Phase 2·NCT06937931·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for IPN10200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPN10200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPN10200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Ipsen

IPN10200

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q4 2028

Trials by Indication[1]

Effectiveness2 trials

Safety and Efficacy1 trial

Spasticity1 trial

Episodic Migraine1 trial

Cervical Dystonia1 trial

References

Drug Info

Quick Facts

Related News